. Author manuscript; available in PMC: 2020 Jul 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2019 Apr 3;25(7):1293–1303. doi: 10.1016/j.bbmt.2019.03.027

Table 4.

GVHD Outcomes

Characteristic	Historical Cohort (n=100)	CIK Study Cohort (n=44)	CIK Recipients Subgroup (n=31)	p values
aGVHD
Cumulative Incidence of aGVHD II-IV, % (95% Cl)	100-day: 12.0% (5.6–18.4%) 1-year: 16.0% (8.8–23.2%)	100-day: 20.5% (8.4–32.5%) 1-year 25.1% (12.0–38.2%)	100-day: 9.7% (0–20.3%) 1-year: 16.3% (2.9–29.7%)	Study versus Historical 100-day: 0.244 1-year: 0.242
				CIK recipient versus Historical 100-day: 0.660 1-year: 0.484
Cumulative Incidence of aGVHD III-IV, % (95% CI)^{^}	100-day: 1.0% (0–3.0%) 1-year: 2.0% (0–4.8%)	100-day: 9.1% (0.5–17.7%) 1-year: 13.7% (3.3–24.2%)	100-day: 3.2% (0–9.6%) 1-year: 9.9% (0–20.8%)	Study versus Historical 100-day: <0.001 1-year: <0.001
				CIK recipient versus Historical 100-day: 0.142 1-year: 0.006
cGVHD
Cumulative Incidence of cGVHD, % (95% Cl)	1-year: 26.0% (17.3–34.7%) 2-year: 30.2% (21.0–39.3%) 3-year: 32.6% (23.2–42.0%)	1-year: 25.8% (12.4–39.2%) 2-year: 28.2% (14.4–42.1%) 3-year: NA	1-year: 30.5% (13.4–47.7%) 2-year: 34.1% (16.3–51.9%) 3-year: NA	Study versus Historical 1-year: 0.982 2-year: 0.829
				CIK recipient versus Historical 1-year: 0.666 2-year: 0.718

^{^}

For comparison of aGVHD III-IV, given small sample size and number of events, results including p-value and confidence intervals need to be interpreted with caution.